{"analyses":[{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.68","groupIds":["OG003"],"nonInferiorityComment":"Correlation","nonInferiorityType":"OTHER","pValue":"0.0445","paramType":"Spearman (r)","paramValue":"0.39","statisticalMethod":"Spearman's rank correlation coeffcieitn"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.10","upperLimit":"0.64","value":"0.31"},{"groupId":"OG001","lowerLimit":"-0.41","upperLimit":"0.42","value":"0.01"},{"groupId":"OG002","lowerLimit":"-0.54","upperLimit":"0.24","value":"-0.18"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"0.68","value":"0.39"},{"groupId":"OG004","lowerLimit":"-0.17","upperLimit":"0.57","value":"0.23"},{"groupId":"OG005","lowerLimit":"-0.42","upperLimit":"0.38","value":"-0.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"28"}],"units":"Participants"}],"description":"Primary Objective 1: To assess whether the novel Magnetic Resonance (MR) protocol and exploratory bone biomarkers can improve quantification of tumour burden in patients with new or relapsed myeloma at baseline assessment, compared to paraprotein levels alone.\n\nThis section examined correlation between baseline bone biomarkers and baseline serum paraprotein in a pooled cohort of patients from Groups 1 and 2, using Spearman's Rank Correlation Coefficients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Baseline measurements of P1NP (Procollagen type 1 N-terminal Propeptide).","id":"OG000","title":"Baseline P1NP"},{"description":"Baseline measurements of CTX-1 (Type I Collagen Cross-Linked C-Telopeptide).","id":"OG001","title":"Baseline CTX-1"},{"description":"Baseline measurements of ALP (Alkaline Phosphatase).","id":"OG002","title":"Baseline ALP"},{"description":"Baseline measurements of DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1).","id":"OG003","title":"Baseline DKK1"},{"description":"Baseline measurements of sclerostin.","id":"OG004","title":"Baseline Sclerostin"},{"description":"Baseline measurements of the ratio between RANKL and OPG (osteoprotegerin).","id":"OG005","title":"Baseline RANKL:OPG"}],"paramType":"NUMBER","populationDescription":"Pooled cohort of patients from Groups 1 and 2 who had measured: i) available baseline serum paraprotein; ii) by baseline bone biomarkers.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Primary Outcome 1: Quantifying Tumour Burden (Correlations With Bone Turnover Markers)","type":"PRIMARY","unitOfMeasure":"Spearman's rank correlation coefficient"}